2008-2009印度原料药产业研究报告 >> 水清木华研究中心

　　在全球原料药市场中，印度扮演着重要的角色。2007年印度原料药产值达到41亿美元。2003-2007年间，印度原料药产值的年均复合增长率高达18.81%。从生产量来看，印度在全球前15大制药国家中名列第四。

　　目前，印度制药行业大约有3000家(中国约有1000多家)原料药工厂、近5000家制剂工厂和2000家生产其他药品的工厂。其中，300家为中、大型工厂，主要原料药厂商有兰伯西公司，阮氏公司、悉普拉、Cadila医疗保健公司、世纪制药公司和Matrix公司。

　　印度原料药公司生产400多种不同的原料药，提供大约10000种制剂。印度国内原料药生产能够满足国内90％以上的需求，其出口几乎遍及世界各地。不过，世界上20多个监管严格的重要国家仍然是其产品的主要流向地，印度出口的原料药60%流向这些国家。美国和欧盟对印度原料药生产厂家管理批准数量的增加，也显示了印度原料药生产厂家正在把重心从半规范化市场转换到更规范的市场。

　　阮氏公司、太阳制药和Wockhardt等领先的印度公司有相当数量的原料药生产，以满足国内和出口的需要。例如：阮氏公司在2007财政年度40%的销售额来自于原料药业务；而Wockhardt公司收入的19%来自于原料药销售；太阳制药公司同一时期收入的18%来自于原料药业务。

2007年印度10大原料药制造厂商

来源：水清木华研究中心

　　印度原料药出口销量在未来几年仍将有较快的增长。塔塔战略管理集团（Tata Strategic Management Group）预计：印度原料药的出口将从2007年的37.5亿美元增长到2012年的127.5亿美元。

　　本报告以120多幅图表资料，提供了在印度生产原料药的28家医药公司的详细分析，包括公司简介、过去几年的营业收入和净利润、主要产品、市场分布和未来发展规划等资料。

India plays an important part in the global API market. The API output value of India was US $4.1 billion in 2007, with the CAGR as high as 18.81% during 2003-2007. And Indian ranks at the fourth in the world in terms of API output.

India currently has about 3000 API factories and 5,000 reagent factories, the key API producers including the Ranbaxy, Dr. Reddy, Cipla Ltd, Cadila Healthcare and Matrix. They are producing more than 400 sorts of API and around 10,000 kinds of reagents, satisfying over 90% of Indian domestic demand.

The pharmaceutical companies such as Dr.Reddy, Wockhardt and Sun Pharmaceuticals are also producing API. In the FY2007, 40% sales of Dr. Reddy were contributed by the API. Similarly, 19% revenues of Wockhardt and 18% revenues of Sun Pharmaceuticals were contributed by the API respectively.

Top Ten API Producers in India, 2007

Source: ResearchInChina

The API export of India will enjoy a rapid growth in the coming years, According to the Tata Strategic Management Group, Indian API export value will increase to US $12.75 billion in 2012 from US $3.75 billion in 2007.

This report gives an in-depth analysis of 28 Indian API Producers, including their profile, operating revenues, net profit, products, market distribution and future developments etc.

全球原料药生产厂商地区分布，2007
印度十大原料药生产公司，2007
Alembic营业收入和利润，2003-2007
Alembic主要的财务数据,2007-2008
Alembic新推出的药品名单,2007-08
Alembic主要的兽类药品
Alembic 的销售额和利润，2007-2008
Alembic的控股形式
Atul营业收入和利润，2003-2007
Atul 医药和中间体部门的市场地位
Aurobindo的营业收入和净利润走势图，2004-2008
Aurobindo主要的财务数据,2006-2008
Aurobindo各种药品的销售额
截至2008年3月31日Aurobindo的主营构成（按地区）
Cadila的营业收入和净利润走势图, 2004-2008
Cadila重要的品牌
Cadila 全球业务分布
Cadila的收入所占比例图
Cadila的研究方向
Cadila的战略规划
Cadila 2009年的规划
Cipla的营业收入和净利润走势图, 2004-2008
Dr. Reddy营业收入和净利润，2003-2007
Dr. Reddy主要原料药产品销售情况, 2006-2008
Dr. Reddy 各类型产品销售情况
Dr. Reddy 原料药销售情况地区分布, 2007-2008
Dishman营业收入和净利润，2003-2007
Divis的营业收入和净利润走势图, 2004-2008
Elder营业收入和净利润走势图, 2004-2008
Elder的各种产品一览表
Elder的主营收成图，FY2006-08
Elder的药品销售金额和股价
Elder的收入和资产，2007-2008
FDC营业收入和净利润走势图，2004-2008
FDC的收入和资产
Glenmark营业收入和净利润走势图,2004-2008
Glenmark主要的财务数据
Glenmark原料药生产线和已经获得的认证
Glenmark四个主要的业务模块
Glenmark的战略规划
2008至2010年Glenmark的战略部署
Hikal营业收入和净利润走势图,2004-2008
Hikal 产品目前已获得的国际认证
Hikal的制药业的发展状况，1997-2005
Hikal的主营构成图
Ind Swift的营业收入和净利润走势图, 2004-2008
截至2008年3月31日Ind Swift的控股模式
Ind Swift 出口收入组成
Ind Swift 经营支出情况
Ind Swift 研发支出情况
IPCA营业收入和净利润走势图, 2004-2008年
Revenue and net profit of IPCA, 2004-2008
截至2008年3月31日IPCA的股权分布
IPCA药品销售金额
2007至2008年IPCA国内药品品牌所占市场份额比例图
IPCA的药品在各大洲的出口份额
1998至2008年IPCA主要的财务数据
JBCPL营业收入和净利润走势图，2004-2008
JBCPL产品销售收入组合，2007-2008
JBCPL销售收入组合（按地区），2007-2008
Lupin营业收入和净利润,2004-2008
Lupin主营产品，2008
Lupin工厂分布图，2008
Lupin产品覆盖率，2008
Lupin商业模式，2008
Lupin销售额增长走势和收益构成，2007-2008
Lupin各市场销售收入情况，2004-2008
Lupin各类产品销售收入情况，2004-2008
2007-08财年Lupin营业收入组合
Lupin各类产品出口情况，2004-2008
2007-08财年Lupin原料药销售收入组成
Lupin原料药销售的主要市场
Lupin战略，2008
Matrix营业收入和净利润，2004-2008
Matrix产品种类及产量，2006-2007
Matrix三种主要产品，2007
Matrix控股模式，2008
Matrix各项产品收入统计，2007-2008
Merck营业收入和净利润，2004-2008
2008年Merck 推出的最新医药产品
Merck经营业绩表现，2007-2008
Orchid营业收入和净利润,2004-2008
Orchid产品，2008
Orchid产品覆盖,2008
Orchid全球市场分布，2008
Orchid 产品研发链条
Pfizer营业收入和净利润走势图,2004-2008
Piramal营业收入和净利润，2004-2008
Piramal 名下品牌，2009
Piramal药品生命周期，2009
Piramal全球外包合作伙伴，2009
Piramal发展战略，2009
Ranbaxy营业收入和净利润，2003-2007
Ranbaxy的商业模式，2007
Ranbaxy的全球业务分布，2007
Ranbaxy的欧洲主要市场，2007
Ranbaxy的新兴市场，2007
Ranbaxy各地区销售额划分图，2007
Ranbaxy无机药物战略，2007
Ranbaxy2012年规划
SCDL营业收入和净利润走势图，2004-2008
Sterling营业收入和净利润走势图，2004-2008
Sun Pharmaceuticals营业收入和净利润,2004-2008
Sun Pharmaceuticals产品构成,2009
Sun Pharmaceuticals收益组成，2009
Sun Pharmaceuticals收益增长走势图，2003-2007
Sun Pharmaceuticals赢利能力走势图，2003-2007
Sun Pharmaceuticals收购业务走势图，1995-2003
Sun Pharmaceuticals同业对比，1992-2007
Sun Pharmaceuticals战略，2009
Torrent Pharmaceuticals营业收入和净利润，2004-2008
Torrent 已引进的先进技术，2005-2007
Torrent Pharmaceuticals主营构成，2006-2007
Torrent Pharmaceuticals各地区销售情况，2006-2008
Unichem营业收入和净利润，2004-2008
Unichem旗下品牌销售对比，2006-2008
Unichem控股模式，2008
Unichem主要财务数据，2005-2008
Wockhardt营业收入和净利润，2003-2007
Wockhardt生产药剂类型，2008
Wockhardt生物药剂价值链，2008
Wockhardt销售额和利润走势图，1992-2007
Wockhardt2008年业务构成（按地区）
Wockhardt业务转变情况,1992-2007年
Wockhardt平衡的投资组合，2008
1997-2007年Wockhardt的八次收购（含收购公司名和金额）

Global API Manufacturing 2007
Top 10 API producers in India, 2007
Revenue and net profit of Alembic，2003-2007
Financial highlight of Alembic, 2007-2008
Number of new products launched by Alembic, 2007-2008
Key products of animal-health of Alembic
Revenue and net profit of Atul，2003-2007
Market position of Pharmaceuticals and Intermediates Department of Atul
Revenue and net profit of Aurobindo, 2004-2008
financial Performance of Aurobindo,2006-2008
Sales of different drugs of Aurobindo
the operational statement of Aurobindo as at March 31,2008(by region)
Revenue and net profit of Cadila, 2004-2008
Strong brand of Cadila
Global operations of Zydus Cadila
Revenue break-up of Cadila
Research focus of Cadila
Strategies for growth momentum of Cadila
Scheme of Cadila for 2009
Revenue and net profit of Cipla, 2004-2008
Revenue and net profit of Dr. Reddy，2003-2007
Revenue from Key API Products of Dr. Reddy, 2006-2008
Consolidated Business-Wise Performance of Dr. Reddy
Geographic Mix of APIs of Dr. Reddy, 2007-2008
Revenue and net profit of Dishman，2003-2007
Revenue and net profit of Divis, 2004-2008
Revenue and net profit of Elder,2004 -2008
Products of Elder
Financial Performance of Elder，FY2006-08
Stocks and sales of finished goods of Elder
Revenue and assets of Elder,2007-2008
Revenue and net profit of FDC,2004-2008
Revenue and assets of FDC
Revenue and net profit of Glenmark, 2004-2008
Financial Performance of Glenmark
Production Lines & Regulatory Approvals of API of Glenmark
Four main business of Glenmark
Growth plans and targets for Glenmark
Key milestones planned for 2008-2010 of Glenmark
Revenue and net profit of Hikal, 2004-2008
Regulatory filing status of current Products of Hikal
Development of pharma pipeline of Hikal，1997-2005
Operational statement of Hikal
Revenue and net profit of Ind Swift, 2004-2008
Shareholding pattern of Ind Swift as on March 31,2008
Composition of export income of Ind Swift
Operating Expenses break-up of Ind Swift
Expenditure of R&D of Ind Swift
Revenue and net profit of IPCA, 2004-2008
Distribution of Shareholding of IPCA as on March 31,2008
Break-up of pharmaceutical sales of IPCA
Domestic branded formulations groupwise contribution for 2007-08 of IPCA
Continentwise exports of IPCA
Financial highlights of IPCA from 1998 to 2008
Revenue and net profit of JBCPL，2004 - 2008
JBCPL Composition of Sales (Formulations & APIs)
JBCPL Composition of Sales (Formulations & APIs)
Revenue and net profit of Lupin, 2004-2008
Products of Lupin，2008
Facilities of Lupin，2008
Products Coverage of Lupin，2008
Business model of Lupin，2008
Sales growth and revenue composition of Lupin，2007-2008
Lupin Consolidated Gross Sales by Market, 2004-2008
Lupin Consolidated Gross Sales by product, 2004-2008
Revenue Composition of Lupin in FY2007-08
Lupin Revenue of Exports by Product, 2004-2008
API Sales of Lupin in FY2007-08
API Key Markets
Strategy of Lupin，2008
Revenue and Net Profit of Matrix，2004-2008
Capacities and production of Matrix，2006-2007
Three principal products of Matrix，2007
Shareholding pattern of Matrix, 2008
Product group-wise performance of Matrix
Revenue and Net Profit of Merck，2004-2008
Pharmaceuticals products of Merck launched during 2008
Operational Performance of Merck, 2007-2008
Revenue and net profit of Orchid, 2004-2008
Products of Orchid ,2008
Product range of Orchid,2008
Global market reach of Orchid，2008
Orchid product development pipeline
Revenue and Net Profit of Pfizer, 2004-2008
Brands holding by Piramal,2009
Drug life-cycle of Piramal,2009
Global outsourcing partner,2009
Strategy of Piramal,2009
Revenue and net profit of Ranbaxy,2003-2007
Business model of Ranbaxy,2007
Global operation of Ranbaxy,2007
Europe-Key Markets of Ranbaxy,2007
Emerging markets of Ranbaxy,2007
Geographic sales split of Ranbaxy, 2007
Inorganic strategy of Ranbaxy,2007
Aspirations of Ranbaxy (2012)
Revenue and net profit of SCDL,2004 - 2008
Revenue and net profit of Sterling,2004 - 2008
Products structure of Sun Pharmaceuticals,2009
Revenue composition of Sun Pharmaceuticals,2009
Growing revenue of Sun Pharmaceuticals,2003-2007
Sustained profitability of Sun Pharmaceuticals,2003-2007
Successful acquisitions of Sun Pharmaceuticals,1995-2003
Peer comparison of Sun Pharmaceuticals,1992-2007
Strategy and approach of Sun Pharmaceuticals,2009
Revenue and net profit of Torrent, 2004-2008
Information in case of imported technology,2005-2007
Sales of Torrent Pharmaceuticals by regions,2006-2008
Revenue and net profit of Unichem,2004-2008
Comparison of power brands of Unichem,2006-2008
Shareholding pattern as on March 31, 2008
Financial highlights of Unichem,2005-2008
Revenue and net profit of Wockhardt,2003-2007
Biopharmaceuticals value chain of Wockhardt,2008
Sales Revenues and Profits of Wockhardt,1992-2007
Global operations of Wockhardt,2008
Operation transformation of Wockhardt in 1992, 2000 and 2007
Balanced portfolio of Wockhardt,2008
Eight acquisitions of Wockhardt,1997-2007